ATE478956T1 - Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs - Google Patents

Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs

Info

Publication number: ATE478956T1
Authority: AT; Austria
Prior art keywords: lag; mhc class; cancer; vaccinations; adjuvants
Prior art date: 1997-07-25

Application number

AT06008545T

Other languages

English (en)

Inventor

Frederique Triebel

Original Assignee

Roussy Inst Gustave

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-25

Filing date

1998-07-23

Publication date

2010-09-15

1998-07-23 Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478956T1 publication Critical patent/ATE478956T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06008545T 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs ATE478956T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP97401800A EP0893507A1 (de)	1997-07-25	1997-07-25	Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs

Publications (1)

Publication Number	Publication Date
ATE478956T1 true ATE478956T1 (de)	2010-09-15

Family

ID=8229825

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT98945090T ATE324455T1 (de)	1997-07-25	1998-07-23	Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
AT06008545T ATE478956T1 (de)	1997-07-25	1998-07-23	Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT98945090T ATE324455T1 (de)	1997-07-25	1998-07-23	Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie

Country Status (20)

Country	Link
US (2)	US6410509B1 (de)
EP (3)	EP0893507A1 (de)
JP (1)	JP4723722B2 (de)
KR (1)	KR100603075B1 (de)
CN (1)	CN1184320C (de)
AT (2)	ATE324455T1 (de)
AU (1)	AU753738B2 (de)
BR (1)	BR9811037A (de)
CA (2)	CA2732570C (de)
DE (2)	DE69834330T2 (de)
DK (1)	DK1002108T3 (de)
EA (3)	EA005405B1 (de)
EE (1)	EE200000039A (de)
ES (1)	ES2262242T3 (de)
HK (1)	HK1030014A1 (de)
IL (2)	IL134212A0 (de)
NO (1)	NO20000378D0 (de)
PT (1)	PT1002108E (de)
UA (1)	UA75322C2 (de)
WO (1)	WO1999004810A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE519779T1 (de) *	2001-09-19	2011-08-15	Roussy Inst Gustave	An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
EP1596871A4 (de)	2003-02-28	2006-08-23	Drew M Pardoll	T-zell-regulierung
KR20050082389A (ko) *	2004-02-18	2005-08-23	메덱스젠 주식회사	직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) *	2004-04-13	2008-02-22	Immutep	Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (de) *	2005-10-19	2007-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
EP2044949A1 (de) *	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
WO2011031139A1 (en)	2009-09-09	2011-03-17	Universiteit Utrecht Holding B.V.	An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar)	2009-11-13	2014-09-16	Laboratories Leti S L Unipersonal	استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
PL2638062T3 (pl)	2010-11-10	2018-11-30	Laboratorios Leti, S.L.	Nowy adiuwant
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103751778B (zh) *	2014-01-28	2016-09-28	复旦大学	3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
ME03558B (de)	2014-03-14	2020-07-20	Novartis Ag	Antikörpermoleküle gegen lag-3 und verwendungen davon
AU2015329070B2 (en)	2014-10-07	2018-11-22	Nec Corporation	Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
US9827308B2 (en)	2014-12-10	2017-11-28	Wisconsin Alumni Research Foundation	Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
TW202115102A (zh)	2015-03-09	2021-04-16	日商賽多利克公司	來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
TWI738646B (zh)	2015-04-07	2021-09-11	日商賽多利克公司	醫藥組成物
JP6925980B2 (ja)	2015-05-13	2021-08-25	アジェナスインコーポレイテッド	がんの処置および予防のためのワクチン
IL274572B2 (en)	2015-07-16	2024-01-01	Biolinerx Ltd	Compositions and methods for treating cancer
US10265379B2 (en)	2015-09-16	2019-04-23	Annabelle Rodriguez Oquendo	Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (en)	2015-09-18	2017-03-23	Rijksuniversiteit Groningen	Long chain inulin for stimulating an immune response
BR112019006075A2 (pt)	2016-10-11	2019-06-18	Cytlimic Inc	medicamento
CN108204958A (zh) *	2016-12-19	2018-06-26	伊缪泰普有限公司	结合测定
JP2021522239A (ja)	2018-04-26	2021-08-30	アジェナスインコーポレイテッド	熱ショックタンパク質結合ペプチド組成物およびその使用方法
CA3114585A1 (en) *	2018-09-27	2020-04-02	Genocea Biosciences, Inc.	Treatment methods
JP2020138940A (ja)	2019-02-28	2020-09-03	テルモ株式会社	治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ226414A (en) *	1987-10-02	1992-07-28	Genentech Inc	Cd4 peptide adhesion variants and their preparation and use
JPH03505039A (ja) *	1988-08-22	1991-11-07	アメリカ合衆国	可溶性ｃｄ４を発現するレトロウイルスベクター、エイズの遺伝子治療法
JPH02231083A (ja) *	1988-08-31	1990-09-13	Eisai Co Ltd	組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) *	1989-03-03	1990-12-23	Microgenesys Inc	Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (de) *	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimärische CD4-Immunoglobulin-Polypeptide
FR2656800B1 (fr) *	1990-01-08	1992-05-15	Roussy Inst Gustave	Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) *	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
EP0681483B1 (de) *	1993-01-26	2005-08-24	The Trustees of the University of Pennsylvania (a corporation of Pennsylvania)	Zusammensetzungen und verfahren zur verabreichung von genetischem material
SE510135C2 (sv) *	1994-05-05	1999-04-19	Berol Nobel Ab	Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
CN1110557C (zh) *	1994-05-06	2003-06-04	古斯达威罗斯研究所	Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
CA2194488A1 (en) *	1994-08-05	1996-02-15	Tod Paul Holler	Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
JP2001506122A (ja) *	1994-12-07	2001-05-15	エフ．ホフマン−ラロシュアーゲー	免疫抑制作用を有するモノクローナル抗体断片
EP0800534A2 (de) *	1994-12-23	1997-10-15	Laboratoires Om S.A.	Verwendung von mhc-ii bindeden und/oder imitierenden molekülen zur vorbeugung und/oder behandlung von entzündlichen krankheiten
EP0869803B1 (de) *	1995-12-28	2003-04-16	The Johns Hopkins University School Of Medicine	Allogene parakrine cytokine tumor impfstoffe

1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/de not_active Withdrawn
1998
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/pt not_active IP Right Cessation
- 1998-07-23 DE DE69834330T patent/DE69834330T2/de not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/en active IP Right Grant
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 EE EEP200000039A patent/EE200000039A/xx unknown
- 1998-07-23 CN CNB988075474A patent/CN1184320C/zh not_active Expired - Lifetime
- 1998-07-23 EA EA200200565A patent/EA005405B1/ru not_active IP Right Cessation
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/ja not_active Expired - Lifetime
- 1998-07-23 ES ES98945090T patent/ES2262242T3/es not_active Expired - Lifetime
- 1998-07-23 EP EP06008545A patent/EP1698701B1/de not_active Expired - Lifetime
- 1998-07-23 CA CA2732570A patent/CA2732570C/en not_active Expired - Lifetime
- 1998-07-23 DE DE69841866T patent/DE69841866D1/de not_active Expired - Lifetime
- 1998-07-23 DK DK98945090T patent/DK1002108T3/da active
- 1998-07-23 UA UA2000020976A patent/UA75322C2/uk unknown
- 1998-07-23 CA CA2293805A patent/CA2293805C/en not_active Expired - Lifetime
- 1998-07-23 EA EA200000161A patent/EA003740B1/ru not_active IP Right Cessation
- 1998-07-23 EP EP98945090A patent/EP1002108B1/de not_active Expired - Lifetime
- 1998-07-23 IL IL13421298A patent/IL134212A0/xx unknown
- 1998-07-23 AT AT98945090T patent/ATE324455T1/de active
- 1998-07-23 AT AT06008545T patent/ATE478956T1/de not_active IP Right Cessation
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/ko not_active IP Right Cessation
- 1998-07-23 EA EA200300092A patent/EA200300092A1/ru unknown
- 1998-07-23 PT PT98945090T patent/PT1002108E/pt unknown
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378D0/no not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
2001
- 2001-01-30 HK HK01100662A patent/HK1030014A1/xx not_active IP Right Cessation
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7109026B2 (en)	2006-09-19
WO1999004810A3 (en)	1999-07-08
EP1698701B1 (de)	2010-08-25
ATE324455T1 (de)	2006-05-15
AU753738B2 (en)	2002-10-24
DE69841866D1 (de)	2010-10-07
CA2732570C (en)	2014-11-18
NO20000378L (no)	2000-01-25
EA200200565A1 (ru)	2002-10-31
CN1184320C (zh)	2005-01-12
EA003740B1 (ru)	2003-08-28
KR100603075B1 (ko)	2006-07-20
BR9811037A (pt)	2000-08-01
US6410509B1 (en)	2002-06-25
EP1002108A2 (de)	2000-05-24
DK1002108T3 (da)	2006-08-21
WO1999004810A2 (en)	1999-02-04
KR20010021706A (ko)	2001-03-15
HK1030014A1 (en)	2001-04-20
EE200000039A (et)	2000-10-16
NO20000378D0 (no)	2000-01-25
US20020192195A1 (en)	2002-12-19
JP4723722B2 (ja)	2011-07-13
DE69834330D1 (de)	2006-06-01
EA005405B1 (ru)	2005-02-24
PT1002108E (pt)	2006-09-29
AU9254798A (en)	1999-02-16
DE69834330T2 (de)	2007-03-29
EA200000161A1 (ru)	2000-10-30
EP0893507A1 (de)	1999-01-27
EP1698701A1 (de)	2006-09-06
IL134212A0 (en)	2001-04-30
EA200300092A1 (ru)	2003-06-26
CA2293805A1 (en)	1999-02-04
CA2732570A1 (en)	1999-02-04
CA2293805C (en)	2011-05-03
IL134212A (en)	2012-03-29
EP1002108B1 (de)	2006-04-26
JP2001510806A (ja)	2001-08-07
CN1265149A (zh)	2000-08-30
UA75322C2 (en)	2006-04-17
ES2262242T3 (es)	2006-11-16

Publication	Publication Date	Title
ATE478956T1 (de)	2010-09-15	Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs
ATE495755T1 (de)	2011-02-15	Vorbeugung und behandlung von amyloidogenischen krankheiten
EP0671920A4 (de)	1996-01-10	Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
ATE410446T1 (de)	2008-10-15	Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
DE69127175D1 (de)	1997-09-11	Antisens-Oligonukleotide zur Behandlung von Krebs
ATE510562T1 (de)	2011-06-15	Anti-ailim antikörper zur behandlung von crohn's
ATE411026T1 (de)	2008-10-15	Mittel zur behandlung der alzheimer-krankheit
DK127688A (da)	1988-09-10	Farmaceutiske praeparater til anvendelse til behandling eller forebyggelse af sygdomme i mavetarmkanalen
DK127788D0 (da)	1988-03-09	Farmaceutiske praeparater til anvendelse til behandling eller forebyggelse af sygdomme i mavetarmkanalen
DE69320646D1 (de)	1998-10-01	Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE101648T1 (de)	1994-03-15	Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
DE69130071D1 (de)	1998-10-01	Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE69124705D1 (de)	1997-03-27	Hexapeptide als liganden des anaphylatoxin-rezeptors
DE69628844D1 (de)	2003-07-31	Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
DE69133068D1 (de)	2002-08-22	Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DK0649433T3 (da)	1998-07-27	Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
TR199802200A2 (xx)	1999-05-21	S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
DE69332956D1 (de)	2003-06-12	Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
ATE345838T1 (de)	2006-12-15	Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
ATE329623T1 (de)	2006-07-15	Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
DE58903550D1 (de)	1993-03-25	Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
DE69503635D1 (de)	1998-08-27	Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
DE68914886D1 (de)	1994-06-01	Mittel zur Behandlung von Raynaud's Krankheit.
PT979093E (pt)	2002-06-28	Agente viral terapeutico que interrompe o desenvolvimento de tumores
SE8902629D0 (sv)	1989-07-31	Ny anvaendning av b-receptorblockerare

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties